InvestorsHub Logo
Followers 155
Posts 20783
Boards Moderated 1
Alias Born 06/26/2002

Re: None

Friday, 12/11/2020 6:24:22 PM

Friday, December 11, 2020 6:24:22 PM

Post# of 5945
The Company is engaged in preliminary discussions with Swiss Growth Forum, a sponsor of a European special purpose acquisition company, "Post Pandemic Recovery Equity" ("the SPAC"), regarding the SPAC's potential merger with an operational subsidiary of the Company to be established in Europe with an exclusive license to crofelemer and Mytesi for the indications of inflammatory diarrhea and HIV-related diarrhea. Jaguar management looks forward to providing updates during the investor call on Thursday, December 17th regarding the progress of the European road show related to this potential merger.

Dial-In Instructions for Investor Call

When: Thursday, December 17, 2020 at 8:30 a.m. Eastern Time

Dial-in (US Toll Free): 888-394-8218

Dial-in (International): 323-701-0225

Conference ID number: 3973780

Live webcast on the investor relations section of Jaguar's website (click here)

Replay Instructions for Investor Call

Dial-in (US Toll Free): 844-512-2921

Dial-in (International): 412-317-6671

Replay Pin Number: 3973780

Replay of the webcast on the investor relations section of Jaguar's website (click here)

About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

"these posts are not of a licensed investment advisor or analyst nor does he give out buy, sell or hold advice to anyone"

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent JAGX News